InvestorsObserver
×
News Home

Do Analysts Expect Sutro Biopharma Inc (STRO) Stock to Rise After It Has Fallen -28.93% in a Month?

Wednesday, May 18, 2022 11:21 AM | InvestorsObserver Analysts

Mentioned in this article

Do Analysts Expect Sutro Biopharma Inc (STRO) Stock to Rise After It Has Fallen -28.93% in a Month?

Wall Street is positive on Sutro Biopharma Inc (STRO). On average, analysts give STRO a Strong Buy rating. The average price target is $29.833, which means analysts expect the stock to rise by 516.38% over the next twelve months. That average ranking earns STRO an Analyst Rating of 72, which is better than 72% of stocks based on data compiled by InvestorsObserver.

Overall Score - 5
Wall Street analysts are rating STRO a Strong Buy today. Find out what this means to you and get the rest of the rankings on STRO!

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Sutro Biopharma Inc Stock Today?

Sutro Biopharma Inc (STRO) stock is trading at $4.84 as of 11:20 AM on Wednesday, May 18, a loss of -$0.26, or -5.1% from the previous closing price of $5.10. The stock has traded between $4.83 and $5.06 so far today. Volume today is below average. So far 42,608 shares have traded compared to average volume of 536,368 shares. Click Here to get the full Stock Report for Sutro Biopharma Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App